Roivant Sciences Ltd (ROIV)
Market Open
21 Jul, 17:07
$
35. 14
+1.09
+3.2012%
$
25.11B Market Cap
- P/E Ratio
- Div Yield
1.56M Volume
- Eps
$ 34.05
Previous Close 
Want to track ROIV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Roivant Sciences: Executing On Huge Buyback Program With More To Come
Roivant Sciences' stock is undervalued with a market cap of $8.37 billion and $6 billion in cash. The company holds stakes in biotech companies worth billions, including Immunovant and Arbutus. Genevant and Arbutus offer potential litigation value of $5-10 billion against Moderna and Pfizer.
Seekingalpha | 2 years ago
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25.
Zacks | 2 years ago
